Table 1.
Clinical characteristics.
| Recipients | Healthy donors | P-value | |
|---|---|---|---|
| Subjects, n | 35 | 20 | – |
| Age, years | 32 (16-58) | 40.5 (19-48) | 0.108 |
| Gender, n (%) | |||
| Male | 15 (42.9) | 11 (55) | 0.753 |
| Female | 20 (57.1) | 9 (45) | |
| Diagnosis, n (%) | |||
| AML | 18 (51.4) | – | – |
| ALL | 10 (28.6) | – | – |
| CML | 1 (2.9) | – | – |
| MDS | 4 (11.4) | – | – |
| others | 2 (5.7) | – | – |
| Donor type | Related donor | ||
| HLA typing | 1–3/6 mismatch | ||
| Stem cell source | BM+PB | ||
| Conditioning regimen | BU+CY+ATG | ||
| GvHD prophylaxis | CSA+MMF+MTX | ||
ATG, antithymocyte globulin; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; BM, bone marrow; BU, busulfan; CML, chronic myeloid leukemia; CSA, cyclosporine A; CY, cyclophosphamide; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MTX, methotrexate; PB, peripheral blood.